DISCLAIMER: THIS PAGE IS INTENDED FOR HEALTHCARE PROFESSIONALS AND OTHER RELEVANT DECISION MAKERS IN United Kingdom - Great Britain ONLY.
Information about the Nuvaxovid XBB.1.5 dispersion for injection, COVID-19 Vaccine (recombinant, adjuvanted) (NVX-CoV2601)
This medicinal product has been granted full marketing authorisation for Great Britain by the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom (U.K.) for Nuvaxovid XBB.1.5 dispersion for injection, COVID-19 Vaccine (recombinant, adjuvanted) (NVX-CoV2601) for active immunization to prevent COVID-19 in individuals aged 12 and older.
If you have any questions or concerns regarding Nuvaxovid XBB.1.5 dispersion for injection, COVID-19 Vaccine (recombinant, adjuvanted) (NVX-CoV2601), please speak to your doctor, nurse or Healthcare Professional.
Report an Adverse Event (AE)
If you are concerned about an adverse event, it should be reported on a Yellow Card. Reporting forms and information can be found at https://coronavirus-yellowcard.mhra.gov.uk/ or search for MHRA Yellow Card on the Google Play or Apple Store. When reporting, please include the vaccine brand and batch/Lot number if available.
Alternatively, adverse events of concern in association with Nuvaxovid XBB.1.5 dispersion for injection, COVID-19 Vaccine (recombinant, adjuvanted) (NVX-CoV2601), can be reported to Novavax Pharmacovigillance at +44 203 5141838 or via the Novavax Adverse Event Reporting Form.
Please do not report the same adverse event(s) to both systems as all reports will be shared between Novavax and MHRA (in anonymised form) and dual reporting will create unnecessary duplicates.
Contact Us
Tel: +44 203 5141838
09:00 - 17:00
Monday - Friday